US Approves Ipsen’s Therapy for Rare Bone Disease
- US approval follows a rejection in Ipsen’s home market
- Ultra-rare disease affects about 800 people globally
This article is for subscribers only.
Ipsen SA’s drug for a debilitating disorder that slowly immobilizes patients within a cage of abnormal bone growth will cost roughly $624,000 a year in the US, after the French drugmaker won clearance there for the first medicine to treat the condition.
The US Food and Drug Administration approved the Paris-based drugmaker’s treatment Sohonos, known generically as palovarotene, on Wednesday for fibrodysplasia ossificans progressiva, often called FOP — an ultra-rare condition in which bone grows in tissue where it isn’t normally present.